Multidrug Resistance Reversal Agents

This publication has 85 references indexed in Scilit:

• The cyclosporin PSC 833 increases survival and delays engraftment of human multidrug-resistant leukemia cells in xenotransplanted NOD-SCID mice
  Leukemia, 2002
• BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
  Annual Review of Pharmacology and Toxicology, 1999
• French multicentric evaluation of mdr1 gene expression by RT-PCR in leukemia and solid tumours. Standardization of RT-PCR and preliminary comparisons between RT-PCR and immunohistochemistry in solid tumours
  Leukemia, 1997
• Phase II study of d-verapamil and doxorubicin in patients with metastatic colorectal cancer
  European Journal Of Cancer, 1993
• Modulation of multidrug-resistant multiple myeloma by cyclosporin
  The Lancet, 1992
• Increased Effectiveness of Liposome-Encapsulated Doxorubicin in Multidrug-Resistant-Transgenic Mice Compared With Free Doxorubicin
  JNCI Journal of the National Cancer Institute, 1992
• Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance
  European Journal Of Cancer, 1992
• Multidrug resistant transgenic mice as a novel pharmacologic tool
  BioEssays, 1991
• Phase I and Pharmacokinetic Trial of Intraperitoneal Etoposide in Combination With the Multidrug-Resistance-Modulating Agent Dipyridamole
  JNCI Journal of the National Cancer Institute, 1991
• Reversal of drug‐resistance in multiple myeloma with verapamil
  British Journal of Haematology, 1988